Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig in Combination With Chemotherapy in Metastatic Pancreatic Cancer
NCT07255404Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of pumitamig in pancreatic ductal adenocarcinoma (PDAC), sponsored by BioNTech SE. Started Dec 2025; status: recruiting.
02
Drugs
pumitamig
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07255404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07255404.